Anthera Pharmaceuticals Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares, Can Purchase 500K Additional Shares to 3.833M Offered at $7.50/Share

Anthera Pharmaceuticals, Inc.

, today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are approximately $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes. Citigroup Global Markets Inc. and Piper Jaffray & Co. acted as joint book-running managers for the offering. SunTrust Robinson Humphrey acted as co-manager. The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on July 13, 2015 and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 800-831-9146 or by email at prospectus@citi.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.